JD
Therapeutic Areas
Amyndas Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AMY-101 | Periodontal Disease / Gingivitis | Phase 2a |
| AMY-101 / Novel C3 inhibitors | Age-Related Macular Degeneration (Geographic Atrophy) | Pre-clinical/Research |
| Drug | Indication | Phase |
|---|---|---|
| AMY-101 | Periodontal Disease / Gingivitis | Phase 2a |
| AMY-101 / Novel C3 inhibitors | Age-Related Macular Degeneration (Geographic Atrophy) | Pre-clinical/Research |